OR WAIT 15 SECS
The transaction will include operations located at different Novasep sites, including its Pompey, France site and sites in the United States, China, and India.
Novasep announced on Jan. 6, 2021 that Sartorius Stedim Biotech, a subgroup of Sartorius, will purchase its chromatography equipment division for an undisclosed amount. The agreement is part of Novasep’s strategy (Rise-2) to focus on core business values.
Novasep’s chromatography equipment division is made up of resin-based batch and intensified chromatography systems that focus on high-pressure, multi-use applications for smaller molecules, including oligonucleotides, peptides, and insulin, Novasep said in a compnay press release. The transaction will include operations at Novasep sites in Pompey, France, and the United States, China, and India.
“This deal marks one of the first steps in our Rise-2 strategic program to focus the group towards our core business,” said Dr. Michel Spagnol, president and CEO of Novasep, in the press release. “We are delighted to strengthen our relationship with the Sartorius team and believe it will be a great opportunity for the chromatography equipment business to fully deliver its potential and accelerate its growth under this new ownership.”
“I am pleased that we will intensify our successful collaboration with the Novasep team, soon to be under the Sartorius roof,” said Dr. René Fáber, head of the Sartorius Bioprocess Solutions Division and executive board member, in the press release. “The Novasep portfolio will perfectly complement our existing chromatography offering and allow us to provide customers with more options for their manufacturing processes. Efficient DSP [downstream processing] has remained a challenge in our industry for years, and Sartorius is committed to helping accelerate and simplify this crucial step so that new drugs can be manufactured much more efficiently.”